Policy & Politics
White House Mandates NIH AIDS Research Funds Be Funneled to New Anthrax Vaccine Development
July 28, 2003
NIH studies on AIDS, tuberculosis, malaria and other infectious diseases may be shortened in length because of a White House mandate stating that NIH should shift funding from existing research in order to finance efforts to develop a new anthrax vaccine, Long Island Newsday reports. More than 500 researchers will be affected by the order, which was announced last month and clarified in a June 2 letter to the Senate Appropriations Committee from Office of Management and Budget Director Joshua Bolten. Funding to develop a new anthrax vaccine was not included in the $1.75 billion appropriated for bioterrorism research for fiscal years 2003 and 2004; however, Congress last year approved $43 million of a $250 million White House request to fund anthrax research. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that Bush administration officials gave NIH the "unprecedented" order to develop a new vaccine without additional funding, Newsday reports. Further, it is the first time the agency has been ordered to conduct a "major applied science program," Fauci said, according to Newsday. Although an anthrax vaccine already exists and is supported by groups such as the American Medical Association, Congress and the Bush administration have called for new vaccines based on "more advanced technology," Newsday reports.
Risk for AIDS-Defining Events Is Greater Among Antiretroviral-Naive Patients Who Don't Achieve CD4+ Cell Count Above 200 on Treatment
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.